Clinical and Dermoscopic Evaluation of Trichloroacetic Acid 20% Versus Long-Pulsed 1064-nm Nd-YAG Laser in the Treatment of Keratosis Pilaris

Dermatol Surg. 2022 Aug 1;48(8):838-842. doi: 10.1097/DSS.0000000000003488. Epub 2022 Jun 15.

Abstract

Background: Keratosis pilaris (KP) is a common disorder of keratinization with different therapeutic modalities; however, none of them is completely satisfactory.

Objective: Assess and compare the efficacy of trichloroacetic acid (TCA) 20% and long-pulsed 1,064-nm Nd:YAG laser in the treatment of KP.

Materials and methods: Twenty patients with symmetrically distributed areas of KP were enrolled in this study. In each patient, 2 symmetrical KP areas were randomly assigned to receive 4 sessions of either long-pulsed Nd:YAG laser or TCA 20%. Clinical evaluation by Investigator Global Assessment (IGA) was done by 2 blinded physicians after treatment. Dermoscopic assessment was done at baseline and at the end point of the study.

Results: Investigator Global Assessment of laser-treated area showed that 2 patients (10%) had moderate improvement, 10 patients (50%) had marked improvement, and 8 patients (40%) had excellent improvement. Investigator Global Assessment of TCA-treated area showed that 9 patients (45%) had marked improvement and 11 patients (55%) had excellent improvement. Dermoscopic score of KP showed a significant reduction with both modalities. The IGA and reduction in dermoscopic scores were comparable between the 2 modalities.

Conclusion: Both long-pulsed 1,064-nm Nd:YAG laser and 20% TCA are effective in the treatment of KP.

Clinical trial registration: Name of the trial register: clinicaltrial.gov . Registration number: NCT04797663.

Publication types

  • Randomized Controlled Trial
  • Comment

MeSH terms

  • Abnormalities, Multiple
  • Darier Disease
  • Eyebrows / abnormalities
  • Humans
  • Immunoglobulin A
  • Lasers, Solid-State* / therapeutic use
  • Treatment Outcome
  • Trichloroacetic Acid / therapeutic use

Substances

  • Immunoglobulin A
  • Trichloroacetic Acid

Supplementary concepts

  • Burnett Schwartz Berberian syndrome

Associated data

  • ClinicalTrials.gov/NCT04797663